Radiopharm Theranostics reports positive Phase 1 imaging data for RAD301
Radiopharm Theranostics said Phase 1 imaging trial data for RAD301 in pancreatic ductal adenocarcinoma patients was positive.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.